Mesoblast capped a horror week on Friday by revealing its trial of a potential treatment for COVID-19 will be wound up because of unexpectedly poor clinical data, as it races to close a critical licensing agreement with Swiss pharmaceutical giant Novartis.
Mesoblast had to pull the pin on a trial treatment for COVID-19. Nicolas Walker
Loading...
Tom Richardson was a journalist at The Australian Financial Review
Carrie LaFrenz is a senior journalist covering retail/consumer goods. She previously covered healthcare/biotech. Carrie has won multiple awards for her journalism including financial journalist of the year from The National Press Club. Connect with Carrie on Twitter. Email Carrie at carrie.lafrenz@afr.com
